Cresset Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cresset Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,000	Closed	-$3.56M	–	1836
2024 Q4	$3.56M	Sell	5,000 -2,300	-32%	-$1.93M	0.02%	412
2024 Q3	$7.67M	Sell	7,300 -800	-10%	-$890K	0.03%	368
2024 Q2	$8.51M	Buy	8,100 +3,700	+84%	+$3.59M	0.04%	319
2024 Q1	$4.23M	Sell	4,400 -400	-8%	-$380K	0.02%	410
2023 Q4	$4.22M	Buy	4,800 +1,400	+41%	+$1.15M	0.03%	382
2023 Q3	$2.8M	Sell	3,400 -246,600	-99%	-$194M	0.01%	448
2023 Q2	$180M	Buy	+250,000	New	+$193M	0.22%	33

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cresset Asset Management's REGN Position: Q2 2026 in Review

Cresset Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 10% in Q2 2026, buying an estimated $181K and bringing the position to 2,803 shares worth $1.75M. The position accounts for 0.01% of the portfolio, ranked #712.

Cresset Asset Management first reported a position in REGN in Q4 2018 and has held it in 29 quarters since. The position peaked at $11M in Q3 2024. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Cresset Asset Management held 2,803 shares of Regeneron Pharmaceuticals worth $1.75M as of Q2 2026.
Cresset Asset Management bought 266 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $181K.
Regeneron Pharmaceuticals made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #712 holding.
Cresset Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
Cresset Asset Management's Regeneron Pharmaceuticals position peaked at $11M in Q3 2024.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.